Welcome to LookChem.com Sign In|Join Free
  • or
2,5-DIMETHOXYISONICOTINALDEHYDE, also known as DIMA, is a chemical compound derived from isonicotinic acid with two methoxy groups attached to the aromatic ring. It is a versatile intermediate in the synthesis of various organic compounds, including pharmaceuticals and agrochemicals. DIMA has demonstrated significant biological activity, and its derivatives are being studied for their potential therapeutic applications in treating diseases such as cancer and neurodegenerative disorders. Furthermore, DIMA has been investigated for its antioxidant and antimicrobial properties, making it a valuable compound for applications in medicine and agriculture.

867267-25-2

Post Buying Request

867267-25-2 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

867267-25-2 Usage

Uses

Used in Pharmaceutical Industry:
2,5-DIMETHOXYISONICOTINALDEHYDE is used as a chemical intermediate for the synthesis of various pharmaceuticals. Its derivatives have been studied for their potential use in treating diseases such as cancer and neurodegenerative disorders due to their significant biological activity.
Used in Agrochemical Industry:
2,5-DIMETHOXYISONICOTINALDEHYDE is used as a chemical intermediate in the synthesis of agrochemicals. Its derivatives may have potential applications in the development of new pesticides or other agricultural products.
Used in Antioxidant Applications:
2,5-DIMETHOXYISONICOTINALDEHYDE is used as an antioxidant in various industries, including food and cosmetics, to prevent oxidation and extend the shelf life of products. Its antioxidant properties can help protect against damage caused by free radicals.
Used in Antimicrobial Applications:
2,5-DIMETHOXYISONICOTINALDEHYDE is used as an antimicrobial agent in various applications, such as in the development of disinfectants and sanitizers. Its antimicrobial properties can help inhibit the growth of harmful microorganisms, contributing to improved hygiene and reduced risk of infection.
Used in Research and Development:
2,5-DIMETHOXYISONICOTINALDEHYDE is used as a research compound in the development of new drugs and other organic compounds. Its unique chemical structure and biological activity make it a valuable tool for exploring new therapeutic targets and applications in medicine and agriculture.

Check Digit Verification of cas no

The CAS Registry Mumber 867267-25-2 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 8,6,7,2,6 and 7 respectively; the second part has 2 digits, 2 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 867267-25:
(8*8)+(7*6)+(6*7)+(5*2)+(4*6)+(3*7)+(2*2)+(1*5)=212
212 % 10 = 2
So 867267-25-2 is a valid CAS Registry Number.
InChI:InChI=1/C8H9NO3/c1-11-7-4-9-8(12-2)3-6(7)5-10/h3-5H,1-2H3

867267-25-2SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 15, 2017

Revision Date: Aug 15, 2017

1.Identification

1.1 GHS Product identifier

Product name 2,5-dimethoxypyridine-4-carbaldehyde

1.2 Other means of identification

Product number -
Other names 2,5-dimethoxy-pyridine-4-carbaldehyde

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:867267-25-2 SDS

867267-25-2Downstream Products

867267-25-2Relevant academic research and scientific papers

Synthetic studies to help elucidate the metabolism of the preclinical candidate TBAJ-876—a less toxic and more potent analogue of bedaquiline

Choi, Peter J.,Conole, Daniel,Sutherland, Hamish S.,Blaser, Adrian,Tong, Amy S.T.,Cooper, Christopher B.,Upton, Anna M.,Palmer, Brian D.,Denny, William A.

, (2020/03/26)

Bedaquiline is a novel drug approved in 2012 by the FDA for treatment of drug-resistant tuberculosis (TB). Although it shows high efficacy towards drug-resistant forms of TB, its use has been limited by the potential for significant side effects. In particular, bedaquiline is a very lipophilic compound with an associated long terminal half-life and shows potent inhibition of the cardiac potassium hERG channel, resulting in QTc interval prolongation in humans that may result in cardiac arrhythmia. To address these issues, we carried out a drug discovery programme to develop an improved second generation analogue of bedaquiline. From this medicinal chemistry program, a candidate (TBAJ-876) has been selected to undergo further preclinical evaluation. During this evaluation, three major metabolites arising from TBAJ-876 were observed in several preclinical animal models. We report here our synthetic efforts to unequivocally structurally characterize these three metabolites through their independent directed synthesis.

3,5-Dialkoxypyridine analogues of bedaquiline are potent antituberculosis agents with minimal inhibition of the hERG channel

Sutherland, Hamish S.,Tong, Amy S.T.,Choi, Peter J.,Blaser, Adrian,Conole, Daniel,Franzblau, Scott G.,Lotlikar, Manisha U.,Cooper, Christopher B.,Upton, Anna M.,Denny, William A.,Palmer, Brian D.

, p. 1292 - 1307 (2019/02/25)

Bedaquiline is a new drug of the diarylquinoline class that has proven to be clinically effective against drug-resistant tuberculosis, but has a cardiac liability (prolongation of the QT interval) due to its potent inhibition of the cardiac potassium channel protein hERG. Bedaquiline is highly lipophilic and has an extremely long terminal half-life, so has the potential for more-than-desired accumulation in tissues during the relatively long treatment durations required to cure TB. The present work is part of a program that seeks to identify a diarylquinoline that is as potent as bedaquiline against Mycobacterium tuberculosis, with lower lipophilicity, higher clearance, and lower risk for QT prolongation. Previous work led to the identification of compounds with greatly-reduced lipophilicity compounds that retain good anti-tubercular activity in vitro and in mouse models of TB, but has not addressed the hERG blockade. We now present compounds where the C-unit naphthalene is replaced by a 3,5-dialkoxy-4-pyridyl, demonstrate more potent in vitro and in vivo anti-tubercular activity, with greatly attenuated hERG blockade. Two examples of this series are in preclinical development.

Solvent-dependent oxidations of 5- and 6-azaindoles to trioxopyrrolopyridines and functionalised azaindoles

Mahiout, Zahia,Lomberget, Thierry,Goncalves, Sylvie,Barret, Roland

supporting information; experimental part, p. 1364 - 1376 (2008/10/09)

A regioselective synthesis of 4,7-dimethoxy 5- and 6-azaindoles 2 has been achieved, based on the appropriate choice of ortho-directing or ortho-repulsing groups in the formylation of a pyridine ring. Studies on the regioselectivity of the formylation step and on the preparation of azidoacrylate intermediates 4 are described in this paper. The reactivity of the 5- and 6-azaindole structures towards BBr3-mediated selective monodemethylation and oxidative demethylation reactions were also investigated. The regioselectivity of the deprotection was confirmed using a chemical approach. Oxidation reactions were then carried out on either dimethoxy- or hydroxymethoxyazaindoles, in different solvents, using [bis(trifluoroacetoxy)iodo]benzene. In acetonitrile-water, trioxopyrrolopyridines 12 were obtained, whereas the formation of functionalised azaindoles 17 was observed in acetonitrile-methanol. The tautomeric structure of the trioxopyrrolopyridines was proved by X-ray diffraction analysis. The Royal Society of Chemistry.

A regioselective route to 5- and 6-azaindoles

Lomberget, Thierry,Radix, Sylvie,Barret, Roland

, p. 2080 - 2082 (2007/10/03)

The synthesis of 4,7-dimethoxy 5- and 6-azaindoles, a structural unit that is present in recently developed anti-HIV-1 agents, was achieved in a regioselective manner. The developed strategy is based on the appropriate choice of a protecting group during a lithium-mediated formylation step, followed by thermal cyclization of azidoacrylates. Georg Thieme Verlag Stuttgart.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 867267-25-2